1,2-cyclohexanedione dioxime | 2258-73-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶二唑类
• 英文名称: 1,2-cyclohexanedione dioxime
• 英文别名: 4,5,6,7-tetrahydro-benzo[1,2,5]oxadiazole；Benzofurazan, 4,5,6,7-tetrahydro-；4,5,6,7-tetrahydro-2,1,3-benzoxadiazole
• CAS: 2258-73-3
• 化学式: C₆H₈N₂O
• 分子量: 124.142
• InChiKey: KKNQZIAWUMQRNK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  38.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1,2-cyclohexanedione dioxime 在 potassium permanganate 、 硫酸 作用下， 生成 4-(2-carboxy-ethyl)-furazan-3-carboxylic acid
  参考文献：
  名称：

  从 1,2-环己二酮二肟形成环己基[c]1,2,5-恶二唑。在液态二氧化硫中尝试用亚硫酰氯进行贝克曼重排

  摘要：

  1,2-环己二酮二肟与亚硫酰氯在液态二氧化硫中的尝试贝克曼重排导致环己基[c] 1,2,5-恶二唑的形成，产率为70%。恶二唑的结构是通过氧化、还原和合成建立的。与苄基二肟的情况相比，讨论了缩合在重排中占主导地位的原因。

  DOI：

  10.1246/bcsj.34.270
• 作为产物：
  描述：

  苯并呋喃 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 为溶剂， 生成 1,2-cyclohexanedione dioxime
  参考文献：
  名称：

  Catalytic hydrogenation of benzo[2.1.3]oxadiazoles

  摘要：

  DOI：

  10.1016/s0040-4020(01)93668-3

文献信息

• NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF
  申请人：Florjancic S. Alan

  公开号：US20080058335A1

  公开（公告）日：2008-03-06

  The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R 1 , R 2 , R 3 , and L 1 are defined in the specfication, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R 1a , R 2a and (Rx)n are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

  本发明涉及式(I)的化合物，或药用盐、前药、前药的盐或其组合物， 其中R 1 ，R 2 ，R 3 和L 1 在规范中定义，包含这种化合物的组合物，以及使用这种化合物和组合物治疗疾病和疾病的方法。本发明还涉及式(II)的化合物，或药用盐、前药、前药的盐或其组合物， 其中R 1a ，R 2a 和(Rx)n如规范中定义，包含这种化合物的组合物，以及使用这种化合物和组合物治疗疾病和疾病的方法。
• [EN] NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF<br/>[FR] NOUVEAUX COMPOSÉS EN TANT QUE LIGANDS DE RÉCEPTEUR DE CANNABINOÏDE ET LEURS UTILISATIONS
  申请人：ABBOTT LAB

  公开号：WO2009067613A1

  公开（公告）日：2009-05-28

  The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, formula (I). wherein R1, R2, R3, R4, and L1 are defined in the specfication, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, formula (II). wherein R1a, R2a, Rx, and n are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

  本发明涉及式(I)的化合物，或药用盐、前药、前药的盐或其组合物，式(I)。其中R1、R2、R3、R4和L1在规范中定义，包括含有这种化合物的组合物，以及使用这种化合物和组合物治疗疾病和疾病的方法。本发明还涉及式(II)的化合物，或药用盐、前药、前药的盐或其组合物，式(II)。其中R1a、R2a、Rx和n如规范中定义，包括含有这种化合物的组合物，以及使用这种化合物和组合物治疗疾病和疾病的方法。
• ORTHO PYRROLIDINE, BENZYL-SUBSTITUTED HETEROCYCLE CCR1 ANTAGONISTS FOR AUTOIMMUNE DISEASES & INFLAMMATION
  申请人：Paradkar Vidyadhar M.

  公开号：US20090093472A1

  公开（公告）日：2009-04-09

  Compounds of the formula are disclosed. The compounds are CCR1 antagonists which are useful for the treatment and prevention of inflammatory and autoimmune diseases. Other embodiments are also disclosed.

  公式为的化合物已被披露。这些化合物是CCR1拮抗剂，可用于治疗和预防炎症性和自身免疫性疾病。其他实施例也已披露。
• Investigations on Steroids. IV. Syntheses of Androstano[2, 3-c]-furazans and Related Compounds
  作者：Genkichi Ohta、Toshio Takegoshi、Katsujiro Ueno、Masao Shimizu

  DOI：10.1248/cpb.13.1445

  日期：——

  Steroids with a furazan ring fused to the 2, 3-positions were synthesized. 2, 3-Dihydroxyiminoandrostanes (III) prepared from androstan-3-ones (I), via 2-hydroxyimino-3-ketones (IV), or 2, 3-diketones (II), were cyclized directly to androstano[2, 3-c]furazans (XVII) by means of alkali, succinic anhydride or thionyl chloride. Alternatively, 2, 3-dihydroxyimino compounds (III) were treated with sodium hypochlorite or lead tetraacetate to afford the corresponding furazan N-oxides (furoxans)(XXI), which were deoxygenated to the furazans (XVII) by heating with triethyl phosphite. Similarly, androst-4-eno and androsta-4, 6-dieno[2, 3-c]furazans (XVII, XIX) were prepared. Syntheses of their derivatives were also described.

  合成了与2, 3-位融合的呋噁环类固醇。通过2-羟基亚氨基-3-酮（IV）或2, 3-二酮（II）从雄甾-3-酮（I）制备的2, 3-二羟基亚氨基雄甾烷（III），在碱、琥珀酸酸酐或氯化亚硫酰的作用下，直接环化生成雄甾烷[2, 3-c]呋噁烷（XVII）。或者，将2, 3-二羟基亚氨基化合物（III）用次氯酸钠或四乙酸铅处理，得到相应的呋噁烷N-氧化物（呋氧烷）（XXI），再通过与三乙基磷酸酯加热处理去氧化为呋噁烷（XVII）。同样，合成了雄甾-4-烯和雄甾-4, 6-二烯[2, 3-c]呋噁烷（XVII, XIX）。还描述了其衍生物的合成。
• Ring expansions of N-methyl-1,2,5-oxadiazolium and 1,2,3-triazolium perchlorate salts with bases to six-membered azines: direct detection of an addition intermediate in an addition–elimination mechanism and a degradation of 1,2,5-oxadiazolium salts to α-cyano nitrones
  作者：Richard N. Butler、Elaine C. McKenna、John M. McMahon、Karen M. Daly、Desmond Cunningham、Patrick McArdle

  DOI：10.1039/a701233k

  日期：——

  α-cyano nitrones via a ring degradation which competes with ring expansion. The reactions with KOBut and LiNPri2 do not involve an addition of the base to the azolium salt. Reactions have been monitored by 13C NMR spectroscopy by using 13CN–. An X-ray crystal structure is reported for (E)-N-(α-cyanobenzylidene)methylamine N-oxide.

  2-甲基-1,2,5-恶二唑高氯酸盐和1-甲基-2-芳基-1,2,3-三重氮高氯酸盐与碱KCN，NaOEt，KOBu t和LiNPr i 2的反应使环扩展为取代的1,2,5-恶二嗪和1,2,4-三嗪 以氰化物为基础，反应遵循加成消除途径，在两种情况下，加成中间体已被分离或通过低温NMR光谱法直接检测到。含有氰化物的恶二唑鎓体系还通过与环扩环竞争的环降解，为α-氰基硝酮提供了一条有用的新途径。与KOBu t和LiNPr i 2的反应不需要将碱加到偶氮盐中。通过使用13 CN –进行13 C NMR光谱监测反应。报告了（E）-N-（α-氰基亚苄基）甲胺N-氧化物的X射线晶体结构。